Stock Financial Ratios, Dividends, Split History
TWIN / Twin Disc, Incorporated financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||252.20|
|Enterprise Value ($M)||306.43|
|Book Value ($M)||135.04|
|Book Value / Share||11.69|
|Price / Book||1.97|
|NCAV / Share||5.12|
|Price / NCAV||4.88|
|Weighted Average Number Of Diluted Shares Outstanding||11,239,000|
|Common Stock Shares Outstanding||11,519,133|
|Weighted Average Number Of Shares Outstanding Basic||11,239,000|
|Common Shares Outstanding||11,572,523|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-0.05|
|Return on Assets (ROA)||-0.03|
|Return on Equity (ROE)||-0.05|
|Identifiers and Descriptors|
|Central Index Key (CIK)||100378|
|SIC 356 - General Industrial Machinery And Equipment|
Stock splits are used by Twin Disc, Incorporated to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Related News Stories
Actuant Corporation (ATU - Free Report) pulled off a positive earnings surprise in the third quarter of fiscal 2018 (ended May 31, 2018), with adjusted earnings per share of 39 cents surpassing the Zacks Consensus Estimate of 36 cents by roughly 8.3%. Also, this industrial tool maker’s adjusted bottom line increased 21.9% from 32 cents per share in the year-ago quarter. This came on the back of healthy segmental business and improving margins. (18-0)
We believe that Chart Industries, Inc. (GTLS - Free Report) is a solid choice for investors who are seeking exposure in the machinery industry. The stock, with roughly $2-billion market capitalization, was upgraded to a Zacks Rank #1 (Strong Buy) on Jun 20. The company delivered better-than-expected results in three of the last four quarters while recording in-line results in one. Average earnings surprise was a positive 23. (11-0)
U.S. manufacturing sector is witnessing resurgence under the Trump administration since last year, shrugging off its long phase of weak productivity and sluggish growth. In fact, U.S. manufacturers are increasing capital spending and hiring on the back of massive tax overhaul, deregulatory measures, strong domestic and global economy and robust business sentiment. (53-0)
We believe that Kadant Inc. (KAI - Free Report) is a solid choice for investors who are seeking exposure in the machinery industry. The stock, with roughly $1.1-billion market capitalization, was upgraded to a Zacks Rank #1 (Strong Buy) on Jun 12. Kadant delivered better-than-expected results in the last four quarters. Average earnings surprise was a positive 15.50%. Notably, its shares have rallied 3. (5-0)
as of ET